Literature DB >> 24971879

Phases I-II Matched Case-Control Study of Human Fetal Liver Cell Transplantation for Treatment of Chronic Liver Disease.

Giada Pietrosi1, Giovanni Vizzini, Jorg Gerlach, Cinzia Chinnici, Angelo Luca, Giandomenico Amico, Monica D'Amato, Pier Giulio Conaldi, Sergio Li Petri, Marco Spada, Fabio Tuzzolino, Luigi Alio, Eva Schmelzer, Bruno Gridelli.   

Abstract

Fetal hepatocytes have a high regenerative capacity. The aim of the study was to assess treatment safety and clinical efficacy of human fetal liver cell transplantation through splenic artery infusion. Patients with end-stage chronic liver disease on the waiting list for liver transplantation were enrolled. A retrospectively selected contemporary matched-pair group served as control. Nonsorted raw fetal liver cell preparations were isolated from therapeutically aborted fetuses. The end points of the study were safety and improvement of the Model for End-Stage Liver Disease (MELD) and Child-Pugh scores. Nine patients received a total of 13 intrasplenic infusions and were compared with 16 patients on standard therapy. There were no side effects related to the infusion procedure. At the end of follow-up, the MELD score (mean ± SD) in the treatment group remained stable from baseline (16.0 ± 2.9) to the last observation (15.7 ± 3.8), while it increased in the control group from 15.3 ± 2.5 to 19 ± 5.7 (p = 0.0437). The Child-Pugh score (mean ± SD) dropped from 10.1 ± 1.5 to 9.1 ± 1.4 in the treatment group and increased from 10.0 ± 1.2 to 11.1 ± 1.6 in the control group (p = 0.0076). All treated patients with history of recurrent portosystemic encephalopathy (PSE) had no further episodes during 1-year follow-up. No improvement was observed in the control group patients with PSE at study inclusion. Treatment was considered a failure in six of the nine patients (three deaths not liver related, one liver transplant, two MELD score increases) compared with 14 of the 16 patients in the control group (six deaths, five of which were caused by liver failure, four liver transplants, and four MELD score increases). Intrasplenic fetal liver cell infusion is a safe and well-tolerated procedure in patients with end-stage chronic liver disease. A positive effect on clinical scores and on encephalopathy emerged from this preliminary study.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24971879     DOI: 10.3727/096368914X682422

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  14 in total

Review 1.  Cell replacement therapies: is it time to reprogram?

Authors:  Harald M Mikkers; Christian Freund; Christine L Mummery; Rob C Hoeben
Journal:  Hum Gene Ther       Date:  2014-09-17       Impact factor: 5.695

2.  A Convenient and Efficient Method to Enrich and Maintain Highly Proliferative Human Fetal Liver Stem Cells.

Authors:  Xuan Guo; Shu Wang; Ya-ling Dou; Xiang-fei Guo; Zhao-li Chen; Xin-wei Wang; Zhi-qiang Shen; Zhi-gang Qiu; Min Jin; Jun-wen Li
Journal:  Rejuvenation Res       Date:  2015-06-10       Impact factor: 4.663

3.  Hepatocyte Transplantation in Special Populations: Clinical Use in Children.

Authors:  Zahida Khan; Stephen C Strom
Journal:  Methods Mol Biol       Date:  2017

4.  Engraftment and Repopulation Potential of Late Gestation Fetal Rat Hepatocytes.

Authors:  Joan M Boylan; Heather Francois-Vaughan; Philip A Gruppuso; Jennifer A Sanders
Journal:  Transplantation       Date:  2017-10       Impact factor: 4.939

Review 5.  Cell therapy in chronic liver disease.

Authors:  Clara T Nicolas; Yujia Wang; Scott L Nyberg
Journal:  Curr Opin Gastroenterol       Date:  2016-05       Impact factor: 3.287

Review 6.  Advances in therapeutic options for portal hypertension.

Authors:  Marina Vilaseca; Sergi Guixé-Muntet; Anabel Fernández-Iglesias; Jordi Gracia-Sancho
Journal:  Therap Adv Gastroenterol       Date:  2018-11-25       Impact factor: 4.409

Review 7.  Functions and the Emerging Role of the Foetal Liver into Regenerative Medicine.

Authors:  Antonella Giancotti; Marco Monti; Lorenzo Nevi; Samira Safarikia; Valentina D’Ambrosio; Roberto Brunelli; Cristina Pajno; Sara Corno; Violante Di Donato; Angela Musella; Michele Francesco Chiappetta; Daniela Bosco; Pierluigi Benedetti Panici; Domenico Alvaro; Vincenzo Cardinale
Journal:  Cells       Date:  2019-08-16       Impact factor: 6.600

8.  Human Amnion-Derived Mesenchymal Stromal Cells in Cirrhotic Patients with Refractory Ascites: A Possible Anti-Inflammatory Therapy for Preventing Spontaneous Bacterial Peritonitis.

Authors:  Mariangela Pampalone; Simona Corrao; Giandomenico Amico; Giampiero Vitale; Rossella Alduino; Pier Giulio Conaldi; Giada Pietrosi
Journal:  Stem Cell Rev Rep       Date:  2021-01-03       Impact factor: 5.739

9.  Biliary Obstruction Promotes Multilineage Differentiation of Hepatic Stem Cells.

Authors:  Mladen I Yovchev; Edward J Lee; Waldemar Rodriguez-Silva; Joseph Locker; Michael Oertel
Journal:  Hepatol Commun       Date:  2019-05-23

Review 10.  Differentiation of Cells Isolated from Afterbirth Tissues into Hepatocyte-Like Cells and Their Potential Clinical Application in Liver Regeneration.

Authors:  Marcin Michalik; Aleksandra Gładyś; Piotr Czekaj
Journal:  Stem Cell Rev Rep       Date:  2020-09-25       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.